301 related articles for article (PubMed ID: 12154044)
1. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid.
Masso-Welch PA; Zangani D; Ip C; Vaughan MM; Shoemaker S; Ramirez RA; Ip MM
Cancer Res; 2002 Aug; 62(15):4383-9. PubMed ID: 12154044
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
3. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic activity of conjugated linoleic acid on basic fibroblast growth factor-induced angiogenesis.
Moon EJ; Lee YM; Kim KW
Oncol Rep; 2003; 10(3):617-21. PubMed ID: 12684633
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
6. Regulation of VEGF and VEGF receptor expression in the rodent mammary gland during pregnancy, lactation, and involution.
Pepper MS; Baetens D; Mandriota SJ; Di Sanza C; Oikemus S; Lane TF; Soriano JV; Montesano R; Iruela-Arispe ML
Dev Dyn; 2000 Jul; 218(3):507-24. PubMed ID: 10878616
[TBL] [Abstract][Full Text] [Related]
7. Multiple differentiation pathways of rat mammary stromal cells in vitro: acquisition of a fibroblast, adipocyte or endothelial phenotype is dependent on hormonal and extracellular matrix stimulation.
Zangani D; Darcy KM; Masso-Welch PA; Bellamy ES; Desole MS; Ip MM
Differentiation; 1999 Jan; 64(2):91-101. PubMed ID: 10234806
[TBL] [Abstract][Full Text] [Related]
8. Interaction with endothelial cells is a prerequisite for branching ductal-alveolar morphogenesis and hyperplasia of preneoplastic human breast epithelial cells: regulation by estrogen.
Shekhar MP; Werdell J; Tait L
Cancer Res; 2000 Jan; 60(2):439-49. PubMed ID: 10667599
[TBL] [Abstract][Full Text] [Related]
9. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
[TBL] [Abstract][Full Text] [Related]
10. Conjugated linoleic acid inhibits proliferation and induces apoptosis of normal rat mammary epithelial cells in primary culture.
Ip MM; Masso-Welch PA; Shoemaker SF; Shea-Eaton WK; Ip C
Exp Cell Res; 1999 Jul; 250(1):22-34. PubMed ID: 10388518
[TBL] [Abstract][Full Text] [Related]
11. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
12. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo.
Al-Khaldi A; Eliopoulos N; Martineau D; Lejeune L; Lachapelle K; Galipeau J
Gene Ther; 2003 Apr; 10(8):621-9. PubMed ID: 12692590
[TBL] [Abstract][Full Text] [Related]
13. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
15. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.
Anand-Apte B; Pepper MS; Voest E; Montesano R; Olsen B; Murphy G; Apte SS; Zetter B
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):817-23. PubMed ID: 9112976
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
Angelov L; Salhia B; Roncari L; McMahon G; Guha A
Cancer Res; 1999 Nov; 59(21):5536-41. PubMed ID: 10554031
[TBL] [Abstract][Full Text] [Related]
19. Decorin suppresses tumor cell-mediated angiogenesis.
Grant DS; Yenisey C; Rose RW; Tootell M; Santra M; Iozzo RV
Oncogene; 2002 Jul; 21(31):4765-77. PubMed ID: 12101415
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
